Laurus Injects Tech In Pharma
Under Satyanarayana Chava, the company has entered cutting-edge areas such as gene therapy and rare diseases.
Under Satyanarayana Chava, the company has entered cutting-edge areas such as gene therapy and rare diseases.
Indian pharma companies have increasingly de-risked their operations by slowly and steadily increasing sales to non-US markets, says India Ratings and Research.
The revenue growth of about 16 leading Indian pharmaceutical companies is estimated to moderate to 6-7% in FY23, says ICRA.